Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
From the American Academy of PediatricsClinical Report

Infectious Diseases Associated With Organized Sports and Outbreak Control

H. Dele Davies, Mary Anne Jackson, Stephen G. Rice, COMMITTEE ON INFECTIOUS DISEASES and COUNCIL ON SPORTS MEDICINE AND FITNESS
Pediatrics October 2017, 140 (4) e20172477; DOI: https://doi.org/10.1542/peds.2017-2477
H. Dele Davies
aPediatric Infectious Diseases and Public Health, University of Nebraska Medical Center, Omaha, Nebraska;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Anne Jackson
bInfectious Diseases, Children’s Mercy Kansas City and Department of Pediatrics, School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen G. Rice
cSports Medicine, Jersey Shore University Medical Center and Department of Pediatrics, Robert Wood Johnson Medical School, Rutgers University, Neptune, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments
Loading
Download PDF

Abstract

Participation in organized sports has a variety of health benefits but also has the potential to expose the athlete to a variety of infectious diseases, some of which may produce outbreaks. Major risk factors for infection include skin-to-skin contact with athletes who have active skin infections, environmental exposures and physical trauma, and sharing of equipment and contact with contaminated fomites. Close contact that is intrinsic to team sports and psychosocial factors associated with adolescence are additional risks. Minimizing risk requires leadership by the organized sports community (including the athlete’s primary care provider) and depends on outlining key hygiene behaviors, recognition, diagnosis, and treatment of common sports-related infections, and the implementation of preventive interventions.

  • Abbreviations:
    GABHS —
    group A β-hemolytic streptococcus
    HG —
    herpes gladiatorum
    HR —
    herpes rugbiorum
    HSV —
    herpes simplex virus
    MMR —
    measles-mumps-rubella
    MRSA —
    methicillin-resistant Staphylococcus aureus
    NATA —
    National Athletic Trainers Association
    NCAA —
    National Collegiate Athletic Association
    NFHS —
    National Federation of State High School Associations
    PCR —
    polymerase chain reaction
    VZV —
    varicella-zoster virus
  • Introduction

    The definition of organized sports includes traditional team sports commonly acknowledged as well as other types of sports (Table 1). Participation in organized sports provides the benefits of (1) physical activity, by engaging in vigorous exercise, achieving fitness, and learning athletic skills; (2) socialization, by experiencing camaraderie and learning teamwork and sportsmanship; and (3) competition, by challenging oneself to perform against others, by striving to continually improve oneself toward achieving one’s full athletic potential, and by learning to win and lose with grace and dignity.1 Organized sports participation, however, can result in the acquisition of a variety of infectious diseases and conditions. Physical contact among athletes, sharing of equipment (such as worn personal protective equipment or braces plus towels, drinking vessels, showers, and locker rooms), and contact with athletic surfaces (mats, artificial turf, dirt, grass, and gym or weight room equipment) can all be responsible for transmission of infection.2–9 In addition, certain organized sports carry specific additional risks; for example, wrestlers practicing in close quarters are especially vulnerable to skin infections.10,11

    View this table:
    • View inline
    • View popup
    TABLE 1

    Examples of Organized Sports Involving North American Children

    Athletes should be taught proper personal hygiene (eg, hand-washing, showering, and proper laundering of uniforms and practice clothing on a daily or regular basis).12–15 Avoidance of sharing of drinking vessels (water bottles, ladles, or cups), mouth guards, towels, braces, batting helmets, personal protective equipment, bars of soap, bath sponges, razors or electric hair shavers, and callus trimmers is also important in reducing infectious risk.2–9 In addition, athletic programs should ensure regular (daily, weekly, and monthly) cleaning of facilities and equipment (eg, weight room, railings, mats, blocking dummies, locker rooms, and showers).16–19 Those who manage sports programs and facilities should develop a plan for proper cleaning and maintenance of a sanitary sporting environment by using guidelines such as those published by the American College of Sports Medicine.20

    Special attention should be paid to proper management of blood and other body fluids.21 Just as hospitals in the United States have concentrated on preventing hospital-associated infections in recent years, the same level of focus on infection prevention and control needs to be present within the organized sports community, including among athletes, parents, coaches, athletic directors, equipment managers, certified athletic trainers, administrators, janitorial staff, team physicians, facility managers, and league officials.

    Although the primary care pediatrician may appear to be peripheral in this athletic milieu of organized sports, leadership from physicians has always been welcome and expected regarding issues of public health and safety. Furthermore, because pediatricians need to provide medical clearance to athletes to participate in organized sports, the preparticipation physical examination is an opportunity to verify that the athlete does not have a skin condition or infection that could be transmitted to others. This visit between the physician and the student athlete allows the primary care pediatrician to deliver anticipatory guidance. Ensuring that immunizations are current per recommendations of the Centers for Disease Control and Prevention, the Advisory Committee on Immunization Practices, and the American Academy of Pediatrics is important, and pediatric providers should identify and document cases in which vaccines are refused or incomplete because of medical exemptions (eg, serious allergy to a vaccine component). Coaches and trainers are primarily responsible for reviewing and stressing to the athlete the key hygiene behaviors needed to minimize the risk of obtaining or spreading infection in organized sports. However, primary care pediatricians can help reinforce such educational messages.

    Organisms Associated With Infections in Athletes

    An athlete can acquire many different infections by participating in organized sports. The pathogens include many that are prominent in outbreaks typically seen in crowded communities or closed community settings or that are facilitated by certain exposures specific to the sport.

    Infectious pathogens include those spread by skin contact (eg, Staphylococcus aureus, group A streptococcal skin infections, Bacillus cereus, herpes simplex virus [HSV], Tinea capitis, Tinea corporis, Tinea pedis, Tinea cruris, Pediculosis capitis, Pediculosis corporis, and Pediculosis pubis), by contaminated food or water (eg, Shiga-toxin producing Escherichia coli, Shigella species, Giardia species, Cryptosporidium species, and norovirus, which is further propagated by the person-to-person route), by respiratory droplet (eg, influenza, pertussis, Neisseria meningitidis, group A streptococcal pharyngitis, mumps), by airborne particles (eg, varicella, measles), or by certain vectors (eg, ticks) (Table 2). In the case of Epstein-Barr virus infection, close contact is required for transmission, and endemic disease within adolescent group settings has been reported (Table 2). Although biologically plausible, there have been no validated reports of infections from transmission of bloodborne pathogens, including hepatitis B, hepatitis C, or HIV during athletic competitions. Nonetheless, the American Academy of Pediatrics has previously issued specific detailed guidelines for management of infections spread by blood and body fluids, including guidance for athletes who are infected with HIV, hepatitis B virus, or hepatitis C virus, and these will not be reiterated in this statement.21

    View this table:
    • View inline
    • View popup
    TABLE 2

    Summary of Epidemiology and Outbreak Management Considerations for Organisms Responsible for Infections in Children Participating in Organized Sports

    Transmission of a specific infectious agent may be affected by a variety of psychosocial (sexually transmitted infection), physical (trauma, closed community contact), and environmental (soil, food, water, vector) factors, especially in an immunologically naïve population. This policy will be focused on diagnosis, treatment, and prevention of the most common infections that may be encountered in the athlete participating in organized sports, with an additional focus on factors that are potentially modifiable. It should be noted that some of the organisms discussed can be transmitted in multiple fashions. Transmission of pathogens spread by contaminated food or water, by respiratory droplets, and by vectors are similar to what can be expected under nonsporting conditions51 and are beyond the scope of this report. Although several of these pathogens are summarized in Table 2, detailed descriptions in this clinical report are provided only for the organisms transmitted primarily by contact, manifesting primarily on the skin, and those that are airborne.

    Infections Primarily Spread by Contact Transmission

    Most sports-related skin infections are spread by contact and have been associated with 10% to 15% of time-loss injuries among athletes at the collegiate level.52 For this reason, routine screening of athletes participating in contact sports during practices and before competitions is important. The Sports Medicine Advisory Committee of the National Federation of State High School Associations (NFHS),53 the National Collegiate Athletic Association (NCAA),54 and the National Athletic Trainers Association (NATA)55 have published guidelines for screening and when to return to athletic participation for several conditions (summarized in Table 3). It is noteworthy that many of the recommendations by these organizations are more stringent than ordinary infection control practices for similar conditions in which the likelihood of the type of close bodily contact is not as significant.

    View this table:
    • View inline
    • View popup
    TABLE 3

    Return to Practice and Competition Guidelines for Infected Athletes

    S Aureus

    Community-acquired methicillin-resistant S aureus (MRSA) is a cause of outbreaks of skin infections among high school and collegiate athletes participating in contact sports, particularly among football players and wrestlers, and is associated with significant morbidity. It manifests primarily as cellulitis or skin abscesses but may lead to invasive disease such as bacteremia, septic arthritis, osteomyelitis, myositis, fasciitis, and pneumonia in up to 10% of cases.56,57 Other noninvasive forms of disease including impetigo, staphylococcal ecthyma, pustulosis, and folliculitis may also pose a risk for transmission of the organism from those so affected. Players who have preexisting skin diseases such as atopic dermatitis may have chronic colonization with S aureus and may be predisposed to recurrent secondary infection. Between 10% and 23% of football players or wrestlers have developed signs and symptoms during outbreaks.5,58–60 Risk factors for infection include skin breaks associated with turf burns or trauma,58 skin-to-skin contact, sharing of equipment or clothing (towels), and higher BMI.5,19,59 Although 4% to 23% of athletes have been found to have colonization with MRSA, high colonization alone does not appear sufficient to trigger an outbreak.61 Wrestling mats, artificial turfs, and football training equipment have been documented with MRSA colonization.19,62,63

    Incidence estimates of MRSA-related skin and soft tissue infections in Nebraska student athletes have ranged from 11.3 to 20.9 per 10 000 football players and 28.1 to 60.8 per 10 000 wrestlers from 2008 to 2012.64 Among 190 high school football players in northeast Ohio who were managed prospectively with nasal swab cultures, 23% displayed methicillin-susceptible S aureus colonization (none carried MRSA). Of the participating athletes, 10 (5.3%) developed skin infections, including 7 with impetigo and 1 with folliculitis barbae during the course of the 2008 season. None of the cultured specimens tested positive for MRSA.65

    Group A Streptococcus

    Group A β-hemolytic Streptococcus (GABHS) has been associated with outbreaks of skin infections after indoor association football tournaments,66 rugby,67,68 and other organized sports. The organism can cause localized skin infections such as pyoderma, cellulitis, or impetigo or invasive infections such as thrombophlebitis, myositis, and sepsis. GABHS has also been associated with outbreaks of pharyngitis among university students (median age 19.5 years) participating in judo.69 Within a 15-day period, 12 of 23 club members in Tokyo, Japan, presented with sore throat and high fever. Diagnosis was made by use of either a rapid streptococcal antigen test or positive throat culture for GABHS when the clinical presentation was suggestive of pharyngitis. Occasionally, outbreaks of invasive GABHS disease have been reported in members of high school football teams,70 likely attributable to sharing of equipment and water bottles.

    Management of S Aureus and GABHS Outbreaks

    Management of MRSA and GABHS outbreaks has been accomplished through meticulous focus on hygiene education, good hygiene practices, prompt identification of infected people, limiting exposure to infected people and contaminated surfaces and objects, decontamination of the environment, and proper treatment and close follow-up of infected people.4,5,7,59,60,69,71 Of particular importance for management of MRSA outbreaks is screening of players for carriage along with use of topical mupirocin for those found to have colonization, use of chlorhexidine washes, and enhancement of personal hygiene practices.7,19,72 Bleach baths (Clorox: regular 6.0% hypochlorite, 5 mL, added to 1 gallon of water) used twice weekly reduced the recurrence rates among children with community-associated S aureus infections by 20% compared with control children managed with routine hygienic measures, but this was not a statistically significant reduction.73 Screening for S aureus and GABHS requires knowledge of what body sites would have colonization. Nasal, skin, vaginal, and rectal carriage are the primary reservoirs for S aureus. In the context of sports-related infections, the primary culture sites should be the nares and any open skin lesions.

    GABHS screening should be performed through vigorous swabbing of a pair of swabs on both tonsils and the posterior pharynx for rapid antigen detection and culture as well as culture of any skin lesions, especially those that are oozing or macerated.23 Measurement of sequential streptococcal antibody titers may also be used to diagnose a recent infection, but this is not recommended for routine use.74

    Skin abscesses are best managed by incision and drainage, with culture of the wound for identification of causative agent and antimicrobial susceptibility pattern along with empirical antibiotic coverage pending culture results. Antibiotic choices should be guided by knowledge of the local patterns of susceptibility of S aureus, especially local rates of MRSA. Methicillin-susceptible S aureus typically is treated with oral penicillinase-resistant β-lactam drugs, such as a first- or second-generation cephalosporin. For patients who are allergic to penicillin, or if MRSA is a significant consideration, the alternatives are trimethoprim-sulfamethoxazole, doxycycline, or clindamycin for susceptible isolates.22 Doxycycline can be used safely in children ages 2 years and older when given for durations less than 2 weeks. Trimethoprim-sulfamethoxazole should not be used as a single agent in the initial treatment of cellulitis because of the possibility it is caused by group A Streptococcus and the possibility of intrinsic resistance of this organism.75–77 Topical mupirocin may be used for localized and nonbullous impetigo. During outbreaks, attempts at eradication of S aureus infections to limit spread may be accomplished by use of topical nasal mupirocin therapy (twice daily for 5–7 days) among people with colonization. However, low-level (minimum inhibitory concentration, 8–256 µg/mL) and high-level (minimum inhibitory concentration, >512 µg/mL) resistance to mupirocin have been identified in S aureus. High-level resistance has been associated with subsequent failure of decolonization.

    GABHS typically is susceptible to penicillin, and this is the usual first-line therapy.74 An oral macrolide or azalide (eg, erythromycin, clarithromycin, or azithromycin) is acceptable for patients who are allergic to penicillin. Duration of treatment is 10 days, with the exception of azithromycin, which is indicated for 5 days. Local mupirocin78–80 or retapamulin81–83 ointment may be useful for limiting person-to-person spread of nonbullous impetigo and for eradicating localized GABHS disease. Guidelines from the NCAA, NFHS, and NATA for when the infected athlete can return to competition for both GABHS and S aureus are summarized in Table 3.

    Prevention of S Aureus and GABHS Outbreaks

    Prevention of infections caused by MRSA and GABHS is achieved primarily through good hygiene practices, not sharing equipment and water bottles, limiting exposure to infected people and contaminated surfaces and objects, decontamination of the environment, and prompt identification, proper treatment, and close follow-up of infected people.4,5,7,59,60,69,71 Athletes with GABHS pharyngitis or skin infections should not return to competitive sports for at least 24 hours after beginning appropriate oral antimicrobial therapy.23 Table 3 summarizes recommendations of the NCAA, NFHS, and NATA for return to competition for patients with S aureus infections, including MRSA.

    Herpes Gladiatorum and Herpes Rugbiorum

    HSV (primarily type 1) has been identified as a cause of outbreak of skin infections among wrestlers (herpes gladiatorum [HG]) and rugby players (herpes rugbiorum [HR]) on numerous occasions, affecting up to 2.6% of high school and 7.6% of college wrestlers in the United States.84–86 During outbreaks, up to 34% of all high school wrestlers have been documented to be infected.87 Risk factors for development of HG-related cutaneous HSV lesions include direct skin-to-skin exposure to opponents with cutaneous lesions.84 There is a range of 4 to 11 days, with an average of 6.80 ± 1.70 days from onset of exposure to development of skin lesions. Most outbreaks (96%) occur on the ventral surface of the body, with up to three-quarters of the cases occurring on areas in direct contact when wrestlers are engaged in the lock-up position (head, face, and neck). Other body areas frequently involved are the extremities (42%) and trunk (28%).16 HSV conjunctivitis (5%) and blepharitis have also been reported.87 Between 25% and 40% of patients with HG and HR will develop constitutional symptoms including fever, chills, sore throat, and headaches.85,87 There are data associating acquired antibody to HSV type 1 infection with protection from acquiring HG, but the association is very weak.84

    Herpes Outbreak and High-Altitude Skiing

    High-altitude skiing also has been associated with relapses of orofacial herpes, presumably because of solar UV radiation exposure, with a median onset of 3.5 days after exposure (strong evidence).88 Although sunscreen with a sun protection factor of 15 was shown to prevent experimental UV light-induced reactivation of herpes labialis compared with placebo,89 it has not been shown to influence the reactivation rate among high-altitude skiers.88

    Management of HG and HR Outbreaks

    There is strong evidence that prompt identification and 3 to 8 days of isolation of infected wrestlers during primary outbreaks of HG and HR with suspension of competition can help contain outbreaks in more than 90% of cases.87,90,91 Diagnosis involves a combination of clinical recognition and may be coupled with cell culture, histologic examination, or rapid diagnostic tests such as direct fluorescent antibody staining, enzyme immunoassay, or polymerase chain reaction (PCR) of vesicular lesion scrapings in complex, lingering, or unclear cases.26 Valacyclovir, 500 mg, every day or twice a day for 7 days, when given within 24 hours of symptoms onset, has been shown to shorten the duration of time until HSV PCR clearance from lesions of adolescent and adult wrestlers with recurrent HG by 21% (from ∼8.1 days with placebo to 6.4 days with valacyclovir).92 Wrestlers receiving valacyclovir should be advised about the importance of good hydration to minimize the risk of nephrotoxicity. Competitors often do not recognize or may deny possible infection. As a result, efforts to reduce transmission should include (1) examination of wrestlers and rugby players for vesicular or ulcerative lesions on exposed areas of their bodies and around their mouths or eyes before practice or competition by a person familiar with the appearance of mucocutaneous infections (including HSV, herpes zoster, and impetigo), (2) excluding athletes with these lesions from competition until all lesions are fully crusted or production of a physician’s written statement indicating that their condition is noninfectious, and (3) cleaning of wrestling mats with a freshly prepared solution of household bleach (1 quarter cup of bleach in 1 gallon of water) applied for a minimum contact time of 15 seconds at least daily and preferably between matches.26 NCAA, NFHS, and NATA guidelines for when the infected athlete can return to competition are summarized in Table 3.

    Prevention of HG and HR Outbreaks

    Athletes with a history of recurrent HG, HR, or herpes labialis should be considered for suppressive antiviral therapy. There is strong evidence that nucleoside analogues (valacyclovir) can suppress recurrent outbreaks of herpes. In a study involving 42 male wrestlers aged 13 to 31 years in Minnesota combining double-blind randomization followed by an open enrollment onto treatment, participants with recurrent HG were treated during the first half of the season with either 500 mg of valacyclovir or placebo and in the second half with 1000 mg of valacyclovir. The 500 and 1000 mg doses of valacyclovir suppressed recurrence of outbreaks among 100% (7 out of 7 and 12 out of 12) of participants whose last recurrence was more than 2 years before. However, the doses were slightly less successful among those with recurrences within 2 years (11 out of 14 and 23 out of 25, respectively), with better results with the 1000 mg dosing.93

    Similarly, in a Minnesota study of 332 male wrestlers 13 to 20 years of age who participated at a 28-day wrestling camp, once-a-day prophylactic valacyclovir (1000 mg) starting 1 week before camp and continuing throughout camp reduced the incidence of clinical HG outbreaks by 87%. Among 55 of these wrestlers who were HSV type 1 immunoglobulin G seronegative at the beginning of the camp and had postcamp serologic testing performed, none developed detectable immunoglobulin M against HSV type 1 or HSV type 2.94 However, there is need for a detailed risk–benefit analysis of using valacyclovir for prophylaxis in wrestlers who are seronegative for herpes.

    Molluscum Contagiosum

    Molluscum contagiosum is a common, benign viral skin infection presenting as skin-colored papules that develop a central umbilication as they age. Molluscum contagiosum affects 5% to 11% of children 0 to 16 years of age95 and most commonly affects the trunk, face, and extremities. Molluscum contagiosum is mostly asymptomatic but may present with pain, itching, redness, or occasionally bacterial superinfection. Outbreaks of molluscum contagiosum have most often been described in association with exposure to swimming in public pools and underlying eczema.3,95–97 Other factors associated with infection include young age (highest incidence in children younger than 14 years), living in close proximity, skin-to-skin contact, sharing of fomites, and residence in tropical climates.3,98

    Management of Molluscum Outbreaks

    Resolution of uncomplicated molluscum contagiosum typically occurs spontaneously in 6 to 12 months, although complete resolution of lesions can take up to 4 years. Although no regimen has proven highly successful, 10% potassium hydroxide and cryotherapy with liquid nitrogen have been used to treat lesions that occur in locations that are cosmetically bothersome to patients or for patients with underlying skin conditions such as eczema. Both forms of treatment appear to have similar efficacy in children, but cryotherapy may be associated with postinflammatory hyperpigmentation or, uncommonly, scarring.99,100 Imiquimod was not shown to be of benefit compared with placebo in randomized controlled trials.101,102 Open-label and observational studies103,104 indicate that cantharidin can be an effective treatment of molluscum contagiosum; however, in 1 small randomized controlled trial of 29 patients, the improvement seen with cantharidin, although greater than with placebo, was not found to be statistically significant.100 Guidelines from the NCAA, NFHS, and NATA for when the infected athlete can return to competition for molluscum are summarized in Table 3.

    Prevention of Molluscum Contagiosum Outbreaks

    Given the known associations of molluscum contagiosum, the best method of prevention would involve avoiding of skin-to-skin contact with people known to have lesions (covering lesions), not sharing towels and other fomites, and limiting exposure to swimming pools that have recently been associated with known outbreaks.

    Tinea Infections

    T corporis and T capitis infections have been reported more frequently among high school wrestlers and judo practitioners (T corporis gladiatorum and T capitis gladiatorum) than among other athletes.8,105⇓⇓⇓⇓⇓⇓–112 Studies of the prevalence of T corporis gladiatorum have involved use of potassium hydroxide examination to aid diagnosis. In 1 such study, 24% of 29 wrestlers had lesions of T corporis, versus 0 in a control group of track team members (P = .005).106 In another study, T corporis was detected in 10 of 19 boys (53%) 15 to 17 years of age belonging to a judo club in Kyoto, Japan.112 The most common cause of T capitis gladiatorum is Trichophyton tonsurans, accounting for more than 80% of cases, but it may also be caused by Trichophyton rubrum and Trichophyton mentagrophytes.113,114 T tonsurans (primarily), T mentagrophytes, and Microsporum canis have also been isolated in high rates during outbreaks of T capitis (ringworm) among high school wrestlers in a wrestling boarding school in Turkey.109,115,116 These organisms have been isolated frequently from individual skin lesions and from wrestling mats.108,109

    Management of T Corporis and T Capitis Outbreaks

    Both skin-based and oral medications are available for the treatment of T corporis, but T capitis is managed exclusively with oral medications, often with simultaneous application of topical treatment to the scalp (because of the need for hair follicle penetration). Skin-based preparations for T corporis include but are not limited to azole creams (clotrimazole, econazole, ketoconazole, oxiconazole), allylamine creams and gels (1% gel of terbinafine and butenafine), and hydroxypyridone (ciclopirox) preparations. Although these all are reasonably effective, some preparations in some studies demonstrate superior cure rates. For example, terbinafine emulsion gel has a mycological cure rate superior to that of ketoconazole cream (94% versus 69%, respectively) with similar adverse events rates.117

    Oral agents also have proven efficacious in the treatment of most cases of T corporis. Different doses and durations of itraconazole have been used in studies. Itraconazole, 100 mg, given orally once a day, was superior to griseofulvin, 500 mg, orally, once a day, when given for 15 days (87% mycological cure rate versus 57%, respectively, at the end of 2 weeks after completion of therapy) to adolescents and adults.118 In contrast, 200 mg of itraconazole was found to be superior to 250 mg of terbinafine when given for 7 days respectively in terms of clinical response rates when administered to adolescents and adults.119

    For T capitis, the traditional treatment in children had been oral griseofulvin, 10 mg/kg per day, microsize formulation, given once daily for 6 to 8 weeks, although doses of griseofulvin as high as 20 to 25 mg/kg per day have been used.120 Terbinafine, 125 or 250 mg (adjusted for age), given for 2 to 8 weeks, has recently been shown to have efficacy that is at least as good, with fewer adverse effects and fewer recurrences.116,121⇓–123 Cochrane reviews have concluded that 4 weeks of terbinafine was equivalent to 8 weeks of griseofulvin.124,125 Similarly, oral fluconazole given for 4 weeks had similar efficacy to oral griseofulvin given for 6 weeks,126,127 although at least 1 study revealed the efficacy to be low for both regimens.128 Itraconazole given for 2 weeks is also similar in efficacy to 6 weeks of griseofulvin, whereas terbinafine and itraconazole appear to have similar efficacy for treatment periods of 2 to 3 weeks.124 However, terbinafine, itraconazole, and fluconazole are significantly more expensive than griseofulvin. Furthermore, griseofulvin appears to be superior for infections attributable to certain species of Microsporum, which may require 4 weeks’ duration or more of therapy with terbinafine and itraconazole.122,129,130 Terbinafine appears superior for T tonsurans.125

    Prevention of T Corporis and T Capitis Outbreaks

    Fluconazole, 100 mg per day for 3 days, given prophylactically before initiation of competitive interscholastic high school wrestling and given again 6 weeks into the season, has been reported to significantly reduce the incidence of T corporis from 67.4% to 3.5%.30 However, the risk-benefit analysis of giving fluconazole prophylactically in this manner has not been determined, and its use should be in consultation with an infectious diseases expert.

    T Pedis

    T pedis (athlete’s foot) presents as a fine scaly or vesiculopustular eruption that is often itchy. The lesions may involve all areas of the foot but commonly include the fissures and scaling between toes. Increased rates of T pedis have been well documented and common among swimmers and runners (especially marathon runners), with documented infections in up to 22%. The predominant causes are T rubrum and T mentagrophytes.131 Spread via direct contact with the organism, T pedis is prevalent in warm, humid environments and affects men more than women.132 Obesity and diabetes are additional risk factors for T pedis.133

    Management of T Pedis Outbreaks

    Numerous treatments (creams and oral medications) have been evaluated for treating T pedis. In randomized controlled trials in adults, ciclopirox olamine (a broad-spectrum hydroxypyridone antifungal with proven efficacy against T rubrum, T mentagrophytes, and Epidermophyton floccosum) cream or gel (0.77%) applied twice daily to the affected areas for 4 weeks has been shown to be effective in eradicating T pedis and superior to 1% clotrimazole cream or ciclopirox vehicle in achieving both clinical and mycological cure (∼60% for cyclopirox olamine cream versus 6% for its vehicle only at end of treatment, and 85% versus 16% two weeks after treatment).134,135 There are no published studies of use of ciclopirox to treat T pedis in children, but a dosage of topical application twice a day is recommended for use in children older than 10 years.28 Similarly, naftifine ointment applied twice daily for 4 weeks and sulconazole nitrate 1% cream applied daily for 4 to 6 weeks have been associated with significantly higher mycological clearance rates (57%–66%) compared with their vehicles alone (13%–34% cleared) and were associated with fewer relapses in treatment of T rubrum–related T pedis.136,137 However, sulconazole is not approved for use in children in the United States. More recently, topical azoles such as fenticonazole powder have been used in adults with up to 100% cure rates.138 Terbinafine 1% cream applied daily for 1 week also has been used effectively to treat T pedis, with >93% mycological cure rate at 4 weeks, and is approved for children 12 years and older.139 Luliconazole was recently reported as a 1% cream trial for T pedis in adults, but less than 50% of the participants were cured on this regimen.140 It is only approved by the US Food and Drug Administration for use in adults.

    Terbinafine offers the advantage of once-daily dosing and can be given for briefer periods than skin-based treatments. Oral terbinafine, 250 mg, given once daily for 1 week, has similar efficacy (based on mycological cure rates at week 4) to 4 weeks of clotrimazole 1% cream applied twice a day but with faster clinical resolution.141 Oral terbinafine, 250 mg, also is similar in mycological efficacy to itraconazole, 100 mg, when given over a 2-week duration but may have a slightly lower rate of relapse. Terbinafine is well tolerated in children, with the most concerning potential adverse events being occasional isolated neutropenia and rare liver failure, typically in people with preexisting liver disease.

    Prevention of T Pedis Outbreaks

    The use of foot powder after bathing has been associated with a decline in the rates of T pedis in a random sampling of users of a swimming bath in Scotland from 8.5% to 2.1% over a 3.5-year period,142 mostly attributable to the decline in rates of T mentagrophytes from 5.3% to 0.5%. Experts believe that careful and thorough drying between the toes after showers, daily changes of socks, and periodic cleaning of athletic footwear can be helpful.

    T Cruris

    T cruris (jock itch or crotch rot) is a common pruritic fungal infection of the groin and adjacent skin.133 Heat, humidity, and hyperhidrosis are predisposing factors, as is wearing of tight-fitting or wet clothing. Similar to T pedis, obesity and diabetes are additional risk factors for T cruris.133

    The predominant cause is T rubrum followed by E floccosum and T mentagrophytes.143,144 It may be spread by contaminated fomites (contaminated towels, hotel bed sheets) or autoinoculation from hands or feet infected with Tinea from another body site (Tinea unguium, T pedis, or Tinea manuum).133

    Management of T Cruris Infection

    Similar to T pedis, terbinafine 1% cream applied daily for 1 week has been used effectively to treat T cruris with a mycological cure rate of approximately 94% and is approved for children 12 years and older.117 Butenafine (a benzylamine derivative of clotrimazole) applied twice daily for 2 weeks and clotrimazole applied twice weekly for 4 weeks are also over-the-counter alternatives, but butenafine is only approved in adults.145⇓⇓–148 Oral itraconazole (100 mg daily for 2 weeks or 200 mg daily for 1 week) has been shown to be effective in adults for treating T cruris and superior to oral griseofulvin (500 mg daily for 2 weeks).118,149,150 Several other azole topical formulations (oxiconazole,151 luliconazole,151 sertaconazole,144 eberconazole152) have been shown to be effective in adults, but none have been studied in any detail in children.

    Prevention of T Cruris Infection

    Because of risk of spread from T pedis, covering active foot lesions with socks before wearing undershorts may reduce the likelihood of direct contamination. Furthermore, complete drying of the crural folds after bathing, and use of separate (clean) towels for drying the groin and other parts of the body may help reduce contamination.

    Verruca Vulgaris

    Verruca vulgaris (common skin warts) are benign epithelial proliferations of the skin and are caused by human papillomaviruses. They are typically painless, multiple in number, and occur on any epithelial surface, although most commonly on the hands, feet, and around and under the nails.33 They may be distinguished from calluses and corns by the presence of black dots (clotted blood vessels that have grown into the wart) when they are pared down as well as the associated loss of overlying dermatoglyphs. Although reports indicate that warts may occur in outbreaks among athletes, there are no published data on the prevalence. Reported risk factors appear to include sharing of equipment and exposure of unshod feet in common shower areas.34 In a study of 146 adolescents who used locker rooms, 27% of those who used communal showers on a regular basis were found to have plantar warts versus only 1.25% of those who only used the locker rooms.34 However, because the children using communal showers were also members of a swim club, it is unclear whether the communal shower or the swimming was the major contributing factor.

    Management of Verruca Vulgaris Infections

    Most cases of common warts will eventually spontaneously regress, with 30% regressing within 6 months and approximately 60% within 2 years. Treatment modalities are usually geared toward chemical or physical destruction of the infected epithelium and include techniques such as freezing with liquid nitrogen, application of salicylic acid-based products or tretinoin (retinoic acid) cream, surgical (paring) or laser removal, and use of topical immunomodulating agents.34 The more destructive methods may lead to pain, which may inhibit athletic activity. More recently, cantharidin combined with podophyllotoxin-salicylic acid has been used in adults and reported to be effective but associated with pain and blistering.153,154

    Prevention of Verruca Vulgaris Infections

    Precise mechanisms of preventing common warts are unknown. However, like most infections that are transmitted by contact, avoidance of contact with people known to have common warts, not sharing equipment and towels, and wearing rubber soled flip-flops or sandals in communal showers may minimize risk.

    Scabies and Lice

    Scabies (caused by Sarcoptes scabiei) and lice (P capitis), although not commonly reported in sports, can be disqualifying if identified in children participating in organized, especially contact, sports. They are transmitted primarily through person-to-person contact. The scabies parasite can survive on clothing for up to 4 days without skin contact.35 Lice do not survive away from the scalp more than 1 to 2 days without a blood meal, and although uncommon, can be transmitted by hair brushes, combs, hats, and hair ornaments.37 The transmission, risk factors, recognition, diagnosis, treatment, and prevention are summarized in Table 2. Successful treatment of scabies can be achieved topically with permethrin 5% cream or oral ivermectin (not for pregnant women), but resistance has been reported to both.155,156 Pregnant women and infants may be treated with topical crotamiton or precipitated sulfur ointment. Head lice treatment requires attention not only to the live lice but also to eggs that may subsequently hatch. Treatment of head lice can be started with over-the-counter 1% permethrin lotion or with pyrethrin combined with piperonyl butoxide, both of which have good safety profiles.36 Resistance to these over-the-counter agents is commonplace in many parts of the United States, and as such, alternative Food and Drug Administration–approved treatments may be necessary. For lice resistant to over-the-counter medications, treatment options include spinosad suspension, benzyl alcohol lotion, malathion, or ivermectin lotion. Spinosad and ivermectin lotion are ovicidal, and a single treatment may be adequate, but no treatment is 100% ovicidal.155,156 Suffocant treatments, such as benzyl alcohol lotion or malathion lotion, require retreatment approximately 1 week later to kill any new lice that hatched from nits. For lice resistant to all topical agents, oral ivermectin in a single dose of 200 or 400 μg/kg may be used in infants weighing over 15 kg, with a second dose given after 9 to 10 days.36

    Infections Primarily Spread by Airborne or Droplet Route

    Varicella-Zoster Virus

    Although varicella has been reported as a cause of airborne sports-related infections,157 such reports are rare in the era of immunization with the live attenuated vaccine against the virus. The varicella-zoster virus (VZV) manifests primarily as a generalized, pruritic, vesicular rash consisting of 250 to 500 lesions in different stages (crops) of development and crusting.39 There is usually an associated low-grade fever, and there may be other systemic symptoms. Disease in vaccinated children is often milder and atypical in nature compared with the wild virus infection and requires a high index of suspicion. Diagnosis is usually made on the basis of a typical clinical picture coupled with history of exposure, but vesicular fluid or scab scraping can be used for confirmation by using PCR, direct fluorescent antibody assay, or VZV-specific culture. A significant increase in serum varicella immunoglobulin G antibody between acute and convalescent serum samples can also assist in diagnosis.

    Management of VZV Infections

    Isolation should be instituted for those suspected to have chickenpox until the diagnosis is either ruled out or all the lesions are crusted over or in vaccinated children when there are no new lesions within a 24-hour period.39 Oral acyclovir or valacyclovir given within 24 hours of rash onset results in only a modest decrease in symptoms and is not routinely recommended for most healthy children. It should be considered in otherwise healthy children who are at increased risk of moderate to severe varicella, including people older than 12 years, people with chronic cutaneous or pulmonary disorders, those receiving long-term salicylate therapy, and those on short, intermittent, or aerosolized courses of corticosteroids.39

    Prevention of VZV Infections

    The most effective proven means of preventing VZV is via primary immunization with the live attenuated vaccine.39 Children exposed to VZV should have their immunity evaluated, either through vaccination records or through serologic testing.

    Measles

    Measles is characterized by a prodrome of cough, coryza, and conjunctivitis with fever followed by maculopapular or morbilliform rash that begins on the face and spreads downward to the trunk and out to the extremities. Koplik spots, which are considered pathognomonic, also appear during the prodrome.40 Patients are contagious 4 days before the rash to 4 days after the rash appears. Measles outbreaks have been reported during many different types of sporting events ranging from gymnastics to skiing and fencing,158⇓⇓⇓⇓–163 highlighting the importance of adequate vaccination of all athletes. Up to 5% of people who have received a single dose of vaccine at 12 months or older have vaccine failure. Among previously immunized people, primary vaccine failure (inadequate response to vaccine) is a more common cause of failure than waning immunity. As a result, the current recommendations call for a 2-dose vaccine schedule for children and high-risk adults.40

    Mumps

    Mumps is a systemic illness that presents with swelling of 1 or more of the salivary glands, typically the parotid glands. Up to one-third of mumps cases do not cause salivary gland swelling, presenting instead as a respiratory tract infection. Orchitis is a common complication after puberty, but it rarely leads to sterility. Approximately 10% of patients have an associated viral meningitis, and numerous other complications occur rarely, including permanent hearing loss, myocarditis, endocardial fibroelastosis, arthritis, thrombocytopenia, thyroiditis, mastitis, glomerulonephritis, pancreatitis, and oophoritis. The virus has been isolated from saliva from 7 days before through 8 days after onset of salivary gland swelling. Before introduction of mumps vaccine, outbreaks of mumps were common in the United States, primarily in crowded settings including schools, prisons, orphanages, and military facilities. Although the incidence of the disease has declined significantly with the introduction of the 2-dose schedule of the measles-mumps-rubella (MMR) vaccine, outbreaks still periodically occur, primarily because of incomplete vaccination.

    Management of Measles and Mumps Outbreaks

    Immunization is the cornerstone of managing measles and mumps outbreaks. All suspected cases of measles or mumps should be reported immediately, and every effort should be made for laboratory confirmation of the infection either through serologic testing or detection of virus from clinical specimens (throat washings, nasopharyngeal secretions, urine, and blood for measles and buccal swabs, throat washings, saliva, or cerebrospinal fluid, if relevant, for mumps). In an outbreak setting, the MMR vaccine should be given to all people (>12 months) who lack evidence of immunity. For mumps, a second MMR dose should be offered to all students (including those in postsecondary school) who have received only 1 dose of MMR vaccine. A second MMR dose should also be considered for both conditions in children 1 to 4 years of age if they have only received 1 dose and there is an ongoing outbreak affecting preschool-aged children with community-wide transmission.40

    Prevention of Measles and Mumps Outbreaks

    The most important method to prevent measles and mumps outbreaks is routine immunization of all children with a live attenuated vaccine, such as MMR or MMR-varicella vaccine, at age 12 through 15 months, with a second dose at 4 to 6 years of age, and people who are not documented to have been vaccinated during these periods.40 People who have altered immunity (except HIV infection, unless they have severe immunosuppression) should not receive MMR vaccine. Furthermore, MMR-varicella vaccine should not be given to patients with HIV (even if these people have little to no immune compromise) because of a lack of safety data at the present time.

    The epidemiology and outbreak control considerations for other conditions primarily transmitted via droplet and contaminated food and water are summarized in Table 2.

    Lead Authors

    H. Dele Davies, MD, MS, MHCM, FAAP

    Mary Anne Jackson, MD, FAAP

    Stephen G. Rice, MD, PhD, MPH, FAAP

    Committee on Infectious Diseases, 2016–2017

    Carrie L. Byington, MD, FAAP, Chairperson

    Yvonne A. Maldonado, MD, FAAP, Vice Chairperson

    Elizabeth D. Barnett MD, FAAP

    James D. Campbell, MD, FAAP

    H. Dele Davies, MD, MS, MHCM, FAAP

    Ruth Lynfield, MD, FAAP

    Flor M. Munoz, MD, FAAP

    Dawn Nolt, MD, MPH, FAAP

    Ann-Christine Nyquist, MD, MSPH, FAAP

    Sean O’Leary, MD, MPH, FAAP

    Mobeen H. Rathore, MD, FAAP

    Mark H. Sawyer, MD, FAAP

    William J. Steinbach, MD, FAAP

    Tina Q. Tan, MD, FAAP

    Theoklis E. Zaoutis, MD, MSCE, FAAP

    Ex Officio

    David W. Kimberlin, MD, FAAP – Red Book Editor

    Michael T. Brady, MD, FAAP – Red Book Associate Editor

    Mary Anne Jackson, MD, FAAP – Red Book Associate Editor

    Sarah S. Long, MD, FAAP – Red Book Associate Editor

    Henry H. Bernstein, DO, MHCM, FAAP – Red Book Online Associate Editor

    H. Cody Meissner, MD, FAAP – Visual Red Book Associate Editor

    Liaisons

    James Stevermer, MD – American Academy of Family Physicians

    Amanda C. Cohn, MD, FAAP – Centers for Disease Control and Prevention

    Karen M. Farizo, MD – US Food and Drug Administration

    Marc Fischer, MD, FAAP – Centers for Disease Control and Prevention

    Bruce G. Gellin, MD, MPH – National Vaccine Program Office

    Richard L. Gorman, MD, FAAP – National Institutes of Health

    Natasha Halasa, MD, MPH, FAAP – Pediatric Infectious Diseases Society

    Joan L. Robinson, MD – Canadian Paediatric Society

    Jamie Deseda-Tous, MD – Sociedad Latinoamericana de Infectologia Pediatrica (SLIPE)

    Geoffrey R. Simon, MD, FAAP – Committee on Practice Ambulatory Medicine

    Jeffrey R. Starke, MD, FAAP – American Thoracic Society

    Staff

    Jennifer M. Frantz, MPH

    Council on Sports Medicine and Fitness Executive Committee, 2016–2017

    Cynthia R. LaBella, MD, FAAP, Chairperson

    Margaret A. Brooks, MD, FAAP

    Greg S. Canty, MD, FAAP

    Alex Diamond, DO, FAAP

    William Hennrikus, MD, FAAP

    Kelsey Logan, MD, FAAP

    Kody A. Moffatt, MD, FAAP

    Blaise Nemeth, MD, FAAP

    Brooke Pengel, MD, FAAP

    Andrew Peterson, MD, FAAP

    Paul Stricker, MD, FAAP

    Liaisons

    Mark Halstead, MD, FAAP – American Medical Society for Sports Medicine

    Donald W. Bagnall – National Athletic Trainers Association

    Consultant

    Neeru A. Jayanthi, MD

    Staff

    Anjie Emanuel, MPH

    Footnotes

    • Address correspondence to H. Dele Davies, MD, MS, MHCM, FAAP. E-mail: dele.davies{at}unmc.edu
    • This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

    • Clinical reports from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, clinical reports from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

    • The guidance in this statement does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

    • All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

    • FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

    • FUNDING: No external funding.

    • POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

    References

    1. ↵
      1. Washington RL,
      2. Bernhardt DT,
      3. Gomez J, et al; Committee on Sports Medicine and Fitness and Committee on School Health
      . Organized sports for children and preadolescents. Pediatrics. 2001;107(6):1459–1462pmid:11389277
      OpenUrlAbstract/FREE Full Text
    2. ↵
      1. Anish EJ
      . Viral hepatitis: sports-related risk. Curr Sports Med Rep. 2004;3(2):100–106pmid:14980139
      OpenUrlPubMed
    3. ↵
      1. Braue A,
      2. Ross G,
      3. Varigos G,
      4. Kelly H
      . Epidemiology and impact of childhood molluscum contagiosum: a case series and critical review of the literature. Pediatr Dermatol. 2005;22(4):287–294pmid:16060861
      OpenUrlCrossRefPubMed
    4. ↵
      1. Centers for Disease Control and Prevention (CDC)
      . Methicillin-resistant staphylococcus aureus infections among competitive sports participants–Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep. 2003;52(33):793–795pmid:12931079
      OpenUrlPubMed
    5. ↵
      1. Centers for Disease Control and Prevention (CDC)
      . Methicillin-resistant Staphylococcus aureus among players on a high school football team–New York City, 2007. MMWR Morb Mortal Wkly Rep. 2009;58(3):52–55pmid:19177039
      OpenUrlPubMed
      1. Choong KY,
      2. Roberts LJ
      . Molluscum contagiosum, swimming and bathing: a clinical analysis. Australas J Dermatol. 1999;40(2):89–92pmid:10333619
      OpenUrlCrossRefPubMed
    6. ↵
      1. Nguyen DM,
      2. Mascola L,
      3. Brancoft E
      . Recurring methicillin-resistant Staphylococcus aureus infections in a football team. Emerg Infect Dis. 2005;11(4):526–532pmid:15829189
      OpenUrlCrossRefPubMed
    7. ↵
      1. Poisson DM,
      2. Rousseau D,
      3. Defo D,
      4. Estève E
      . Outbreak of tinea corporis gladiatorum, a fungal skin infection due to Trichophyton tonsurans, in a French high level judo team. Euro Surveill. 2005;10(9):187–190pmid:16280611
      OpenUrlPubMed
    8. ↵
      1. Redziniak DE,
      2. Diduch DR,
      3. Turman K, et al
      . Methicillin-resistant Staphylococcus aureus (MRSA) in the athlete. Int J Sports Med. 2009;30(8):557–562pmid:19468969
      OpenUrlCrossRefPubMed
    9. ↵
      1. Anderson BJ
      . Skin infections in Minnesota high school state tournament wrestlers: 1997-2006. Clin J Sport Med. 2007;17(6):478–480pmid:17993791
      OpenUrlPubMed
    10. ↵
      1. Wilson EK,
      2. Deweber K,
      3. Berry JW,
      4. Wilckens JH
      . Cutaneous infections in wrestlers. Sports Health. 2013;5(5):423–437pmid:24427413
      OpenUrlCrossRefPubMed
    11. ↵
      1. Daly P,
      2. Gustafson R
      . Public health recommendations for athletes attending sporting events. Clin J Sport Med. 2011;21(1):67–70pmid:21200174
      OpenUrlPubMed
      1. Howe WB
      . Preventing infectious disease in sports. Phys Sportsmed. 2003;31(2):23–29pmid:20086454
      OpenUrlPubMed
      1. Tillett E,
      2. Loosemore M
      . Setting standards for the prevention and management of travellers’ diarrhoea in elite athletes: an audit of one team during the Youth Commonwealth Games in India. Br J Sports Med. 2009;43(13):1045–1048pmid:19858110
      OpenUrlAbstract/FREE Full Text
    12. ↵
      1. Centers for Disease Control and Prevention (CDC)
      . Microbes in pool filter backwash as evidence of the need for improved swimmer hygiene - metro-Atlanta, Georgia, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(19):385–388pmid:23677046
      OpenUrlPubMed
    13. ↵
      1. Anderson BJ
      . The epidemiology and clinical analysis of several outbreaks of herpes gladiatorum. Med Sci Sports Exerc. 2003;35(11):1809–1814pmid:14600542
      OpenUrlCrossRefPubMed
      1. Hostetter KS,
      2. Lux M,
      3. Shelley K,
      4. Drummond JL,
      5. Laguna P
      . MRSA as a health concern in athletic facilities. J Environ Health. 2011;74(1):18–25; quiz 42pmid:21830686
      OpenUrlPubMed
      1. Jessee KB,
      2. Middlemas DA,
      3. Mulder DK,
      4. Rehberg RS
      . Exposure of athletic trainers to potentially infectious bodily fluids in the high school setting. J Athl Train. 1997;32(4):320–322pmid:16558466
      OpenUrlPubMed
    14. ↵
      1. Oller AR,
      2. Province L,
      3. Curless B
      . Staphylococcus aureus recovery from environmental and human locations in 2 collegiate athletic teams. J Athl Train. 2010;45(3):222–229pmid:20446834
      OpenUrlCrossRefPubMed
    15. ↵
      1. American College of Sports Medicine
      . Health/Fitness Facility Standards and Guidelines. 4th ed. Champaign, IL: Human Kinetics; 2012
    16. ↵
      1. American Academy of Pediatrics
      . Infections spread by blood and body fluids. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:158–161. (2018 edition in press)
    17. ↵
      1. American Academy of Pediatrics
      . Staphylococcal infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:715–732. (2018 edition in press)
    18. ↵
      1. American Academy of Pediatrics
      . Group A streptococcal infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:732–744. (2018 edition in press)
      1. American Academy of Pediatrics
      . Bacillus cereus Infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:255–256. (2018 edition in press)
      1. Centers for Disease Control and Prevention (CDC)
      . Outbreak of cutaneous Bacillus cereus infections among cadets in a university military program–Georgia, August 2004. MMWR Morb Mortal Wkly Rep. 2005;54(48):1233–1235pmid:16340940
      OpenUrlPubMed
    19. ↵
      1. American Academy of Pediatrics
      . Herpes simplex. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:432–445. (2018 edition in press)
      1. American Academy of Pediatrics
      . Molluscum contagiosum. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:561–562. (2018 edition in press)
    20. ↵
      1. American Academy of Pediatrics
      . Tinea capitis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30 ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:778–783. (2018 edition in press)
      1. American Academy of Pediatrics
      . Tinea corporis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:781–783. (2018 edition in press)
    21. ↵
      1. Brickman K,
      2. Einstein E,
      3. Sinha S,
      4. Ryno J,
      5. Guiness M
      . Fluconazole as a prophylactic measure for tinea gladiatorum in high school wrestlers. Clin J Sport Med. 2009;19(5):412–414pmid:19741315
      OpenUrlCrossRefPubMed
      1. American Academy of Pediatrics
      . Tinea pedis and tinea unguium. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:784–786. (2018 edition in press)
      1. American Academy of Pediatrics
      . Tinea cruris. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:783–784. (2018 edition in press)
    22. ↵
      1. American Academy of Pediatrics
      . Human papillomaviruses. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:576–583. (2018 edition in press)
    23. ↵
      1. Johnson LW
      . Communal showers and the risk of plantar warts. J Fam Pract. 1995;40(2):136–138pmid:7852935
      OpenUrlPubMed
    24. ↵
      1. American Academy of Pediatrics
      . Scabies. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:702–704. (2018 edition in press)
    25. ↵
      1. American Academy of Pediatrics
      . Pediculosis capitis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:597–601. (2018 edition in press)
    26. ↵
      1. American Academy of Pediatrics
      . Infections spread by direct contact. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:156–157. (2018 edition in press)
      1. American Academy of Pediatrics
      . Epstein-Barr virus infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:336–340. (2018 edition in press)
    27. ↵
      1. American Academy of Pediatrics
      . Varicella-zoster virus infections. In: Kimberlin D, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:846–860. (2018 edition in press)
    28. ↵
      1. American Academy of Pediatrics
      . Measles. In: Kimberlin D, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:535–547. (2018 edition in press)
      1. American Academy of Pediatrics
      . Mumps. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2016:564–568. (2018 edition in press)
      1. American Academy of Pediatrics
      . Influenza. In: Kimberlin DW, Brady MT, Jackson MA, Long, SS, ed. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:476–493. (2018 edition in press)
      1. American Academy of Pediatrics
      . Pertussis (whooping cough). In: Kimberlin D, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:608–621. (2018 edition in press)
      1. American Academy of Pediatrics
      . Meningococcal infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:547–558. (2018 edition in press)
      1. American Academy of Pediatrics
      . Shigella. In: Kimberlin DW, Brady MT, Jackson MA, Long, SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015:706–709. (2018 edition in press)
      1. American Academy of Pediatrics
      . Giardia intestinalis (formerly Giardia lamblia and Giardia duodenalis) infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:353–355. (2018 edition in press)
      1. American Academy of Pediatrics
      . Cryptosporodiosis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:312–315. (2018 edition in press)
      1. American Academy of Pediatrics
      . Norovirus and other human calicivirus infections. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:573–574. (2018 edition in press)
      1. American Academy of Pediatrics
      . Leptospirosis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2015:510–513. (2018 edition in press)
      1. Brockmann S,
      2. Piechotowski I,
      3. Bock-Hensley O, et al
      . Outbreak of leptospirosis among triathlon participants in Germany, 2006. BMC Infect Dis. 2010;10:91
      OpenUrlCrossRefPubMed
    29. ↵
      1. American Academy of Pediatrics
      . Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015. (2018 edition in press)
    30. ↵
      1. Johnson R
      . Herpes gladiatorum and other skin diseases. Clin Sports Med. 2004;23(3):473–484, xpmid:15262383
      OpenUrlCrossRefPubMed
    31. ↵
      1. National Federation of State High School Association, Sports Medicine Advisory Committee
      . Sports related skin infections position statement and guidelines. 2014. Available at: https://www.nfhs.org/sports-resource-content/sports-related-skin-infections-position-statement-and-guidelines/. Accessed March 7, 2017
    32. ↵
      1. National Collegiate Athletic Association
      . 2014-15 NCAA Sports Medicine Handbook. 25th ed. Indianapolis, IN: National Collegiate Athletic Association; 2014
    33. ↵
      1. Zinder SM,
      2. Basler RS,
      3. Foley J,
      4. Scarlata C,
      5. Vasily DB
      . National athletic trainers’ association position statement: skin diseases. J Athl Train. 2010;45(4):411–428pmid:20617918
      OpenUrlCrossRefPubMed
    34. ↵
      1. Gouveia C,
      2. Gavino A,
      3. Bouchami O, et al
      . Community-associated methicillin-resistant Staphylococcus aureus lacking PVL, as a cause of severe invasive infection treated with linezolid. Case Rep Pediatr. 2013;2013:727824
      OpenUrlPubMed
    35. ↵
      1. Lu D,
      2. Holtom P
      . Community-acquired methicillin-resistant Staphylococcus aureus, a new player in sports medicine. Curr Sports Med Rep. 2005;4(5):265–270pmid:16144584
      OpenUrlCrossRefPubMed
    36. ↵
      1. Begier EM,
      2. Frenette K,
      3. Barrett NL, et al; Connecticut Bioterrorism Field Epidemiology Response Team
      . A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis. 2004;39(10):1446–1453pmid:15546080
      OpenUrlCrossRefPubMed
    37. ↵
      1. Hall AJ,
      2. Bixler D,
      3. Haddy LE
      . Multiclonal outbreak of methicillin-resistant Staphylococcus aureus infections on a collegiate football team. Epidemiol Infect. 2009;137(1):85–93pmid:18419855
      OpenUrlCrossRefPubMed
    38. ↵
      1. Lindenmayer JM,
      2. Schoenfeld S,
      3. O’Grady R,
      4. Carney JK
      . Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. Arch Intern Med. 1998;158(8):895–899pmid:9570176
      OpenUrlCrossRefPubMed
    39. ↵
      1. Creech CB,
      2. Saye E,
      3. McKenna BD, et al
      . One-year surveillance of methicillin-resistant Staphylococcus aureus nasal colonization and skin and soft tissue infections in collegiate athletes. Arch Pediatr Adolesc Med. 2010;164(7):615–620pmid:20603460
      OpenUrlCrossRefPubMed
    40. ↵
      1. Stanforth B,
      2. Krause A,
      3. Starkey C,
      4. Ryan TJ
      . Prevalence of community-associated methicillin-resistant Staphylococcus aureus in high school wrestling environments. J Environ Health. 2010;72(6):12–16pmid:20104828
      OpenUrlPubMed
    41. ↵
      1. Waninger KN,
      2. Rooney TP,
      3. Miller JE,
      4. Berberian J,
      5. Fujimoto A,
      6. Buttaro BA
      . Community-associated methicillin-resistant Staphylococcus aureus survival on artificial turf substrates. Med Sci Sports Exerc. 2011;43(5):779–784pmid:20962684
      OpenUrlPubMed
    42. ↵
      1. Buss BF,
      2. Connolly S
      . Surveillance of physician-diagnosed skin and soft tissue infections consistent with methicillin-resistant Staphylococcus aureus (MRSA) among Nebraska high school athletes, 2008-2012. J Sch Nurs. 2014;30(1):42–48pmid:23727844
      OpenUrlCrossRefPubMed
    43. ↵
      1. Lear A,
      2. McCord G,
      3. Peiffer J,
      4. Watkins RR,
      5. Parikh A,
      6. Warrington S
      . Incidence of Staphylococcus aureus nasal colonization and soft tissue infection among high school football players. J Am Board Fam Med. 2011;24(4):429–435pmid:21737768
      OpenUrlAbstract/FREE Full Text
    44. ↵
      1. Falck G
      . Group A streptococcal skin infections after indoor association football tournament. Lancet. 1996;347(9004):840–841pmid:8622380
      OpenUrlPubMed
    45. ↵
      1. Ludlam H,
      2. Cookson B
      . Scrum kidney: epidemic pyoderma caused by a nephritogenic Streptococcus pyogenes in a rugby team. Lancet. 1986;2(8502):331–333pmid:2874337
      OpenUrlPubMed
    46. ↵
      1. Quoilin S,
      2. Lambion N,
      3. Mak R, et al
      . Soft tissue infections in Belgian rugby players due to Streptococcus pyogenes emm type 81. Euro Surveill. 2006;11(12):E061221.2
      OpenUrlPubMed
    47. ↵
      1. Aoki A,
      2. Ashizawa T,
      3. Ebata A,
      4. Nasu Y,
      5. Fujii T.
      Group A Streptococcus pharyngitis outbreak among university students in a judo club. J Infect Chemother. 2014;20(3):190–193
      OpenUrl
    48. ↵
      1. Manning SE,
      2. Lee E,
      3. Bambino M, et al
      . Invasive group A streptococcal infection in high school football players, New York City, 2003. Emerg Infect Dis. 2005;11(1):146–149pmid:15705342
      OpenUrlCrossRefPubMed
    49. ↵
      1. Benjamin HJ,
      2. Nikore V,
      3. Takagishi J
      . Practical management: community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA): the latest sports epidemic. Clin J Sport Med. 2007;17(5):393–397pmid:17873553
      OpenUrlCrossRefPubMed
    50. ↵
      1. Archibald LK,
      2. Shapiro J,
      3. Pass A,
      4. Rand K,
      5. Southwick F
      . Methicillin-resistant Staphylococcus aureus infection in a college football team: risk factors outside the locker room and playing field. Infect Control Hosp Epidemiol. 2008;29(5):450–453pmid:18419370
      OpenUrlCrossRefPubMed
    51. ↵
      1. Kaplan SL,
      2. Forbes A,
      3. Hammerman WA, et al
      . Randomized trial of “bleach baths” plus routine hygienic measures vs. routine hygienic measures alone for prevention of recurrent infections. Clin Infect Dis. 2014;58(5):679–682pmid:24265356
      OpenUrlCrossRefPubMed
    52. ↵
      1. Bisno AL,
      2. Gerber MA,
      3. Gwaltney JM Jr,
      4. Kaplan EL,
      5. Schwartz RH; Infectious Diseases Society of America
      . Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis. 2002;35(2):113–125pmid:12087516
      OpenUrlCrossRefPubMed
    53. ↵
      1. Hoskins TW,
      2. Bernstein LS
      . Trimethoprim/sulphadiazine compared with penicillin V in the treatment of streptococcal throat infections. J Antimicrob Chemother. 1981;8(6):495–496pmid:6801003
      OpenUrlCrossRefPubMed
      1. Kaplan EL,
      2. Johnson DR,
      3. Del Rosario MC,
      4. Horn DL
      . Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis J. 1999;18(12):1069–1072pmid:10608626
      OpenUrlCrossRefPubMed
    54. ↵
      1. Traub WH,
      2. Leonhard B
      . Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy. 1997;43(1):10–20pmid:8996736
      OpenUrlCrossRefPubMed
    55. ↵
      1. Dagan R,
      2. Bar-David Y
      . Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 1992;36(2):287–290pmid:1605593
      OpenUrlAbstract/FREE Full Text
      1. George A,
      2. Rubin G
      . A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003;53(491):480–487pmid:12939895
      OpenUrlAbstract/FREE Full Text
    56. ↵
      1. Goldfarb J,
      2. Crenshaw D,
      3. O’Horo J,
      4. Lemon E,
      5. Blumer JL
      . Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob Agents Chemother. 1988;32(12):1780–1783pmid:3149884
      OpenUrlAbstract/FREE Full Text
    57. ↵
      1. Koning S,
      2. van der Wouden JC,
      3. Chosidow O, et al
      . Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008;158(5):1077–1082pmid:18341664
      OpenUrlCrossRefPubMed
      1. Oranje AP,
      2. Chosidow O,
      3. Sacchidanand S, et al; TOC100224 Study Team
      . Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007;215(4):331–340pmid:17911992
      OpenUrlCrossRefPubMed
    58. ↵
      1. Weinberg JM,
      2. Tyring SK
      . Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol. 2010;9(10):1198–1204pmid:20941943
      OpenUrlPubMed
    59. ↵
      1. Becker TM,
      2. Kodsi R,
      3. Bailey P,
      4. Lee F,
      5. Levandowski R,
      6. Nahmias AJ
      . Grappling with herpes: herpes gladiatorum. Am J Sports Med. 1988;16(6):665–669pmid:2853577
      OpenUrlCrossRefPubMed
    60. ↵
      1. Skinner GR,
      2. Davies J,
      3. Ahmad A,
      4. McLeish P,
      5. Buchan A
      . An outbreak of herpes rugbiorum managed by vaccination of players and sociosexual contacts. J Infect. 1996;33(3):163–167pmid:8945704
      OpenUrlCrossRefPubMed
    61. ↵
      1. Dworkin MS,
      2. Shoemaker PC,
      3. Spitters C, et al
      . Endemic spread of herpes simplex virus type 1 among adolescent wrestlers and their coaches. Pediatr Infect Dis J. 1999;18(12):1108–1109pmid:10608638
      OpenUrlCrossRefPubMed
    62. ↵
      1. Belongia EA,
      2. Goodman JL,
      3. Holland EJ, et al
      . An outbreak of herpes gladiatorum at a high-school wrestling camp. N Engl J Med. 1991;325(13):906–910pmid:1652687
      OpenUrlCrossRefPubMed
    63. ↵
      1. Mills J,
      2. Hauer L,
      3. Gottlieb A,
      4. Dromgoole S,
      5. Spruance S
      . Recurrent herpes labialis in skiers. Clinical observations and effect of sunscreen. Am J Sports Med. 1987;15(1):76–78pmid:3812864
      OpenUrlCrossRefPubMed
    64. ↵
      1. Rooney JF,
      2. Bryson Y,
      3. Mannix ML, et al
      . Prevention of ultraviolet-light-induced herpes labialis by sunscreen. Lancet. 1991;338(8780):1419–1422pmid:1683420
      OpenUrlCrossRefPubMed
    65. ↵
      1. Anderson BJ
      . Managing herpes gladiatorum outbreaks in competitive wrestling: the 2007 Minnesota experience. Curr Sports Med Rep. 2008;7(6):323–327pmid:19005353
      OpenUrlPubMed
    66. ↵
      1. Stacey A,
      2. Atkins B
      . Infectious diseases in rugby players: incidence, treatment and prevention. Sports Med. 2000;29(3):211–220pmid:10739269
      OpenUrlPubMed
    67. ↵
      1. Anderson BJ
      . Valacyclovir to expedite the clearance of recurrent herpes gladiatorum. Clin J Sport Med. 2005;15(5):364–366pmid:16162997
      OpenUrlCrossRefPubMed
    68. ↵
      1. Anderson BJ
      . The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers. Clin J Sport Med. 1999;9(2):86–90pmid:10442623
      OpenUrlCrossRefPubMed
    69. ↵
      1. Anderson BJ
      . Prophylactic valacyclovir to prevent outbreaks of primary herpes gladiatorum at a 28-day wrestling camp. Jpn J Infect Dis. 2006;59(1):6–9pmid:16495626
      OpenUrlPubMed
    70. ↵
      1. Olsen JR,
      2. Gallacher J,
      3. Piguet V,
      4. Francis NA
      . Epidemiology of molluscum contagiosum in children: a systematic review. Fam Pract. 2014;31(2):130–136pmid:24297468
      OpenUrlCrossRefPubMed
      1. Castilla MT,
      2. Sanzo JM,
      3. Fuentes S
      . Molluscum contagiosum in children and its relationship to attendance at swimming-pools: an epidemiological study. Dermatology. 1995;191(2):165pmid:8520069
      OpenUrlCrossRefPubMed
    71. ↵
      1. Niizeki K,
      2. Kano O,
      3. Kondo Y
      . An epidemic study of molluscum contagiosum. Relationship to swimming. Dermatologica. 1984;169(4):197–198pmid:6500123
      OpenUrlCrossRefPubMed
    72. ↵
      1. Thompson AJ,
      2. Matinpour K,
      3. Hardin J,
      4. Hsu S
      . Molluscum gladiatorum. Dermatol Online J. 2014;20(6)pmid:24945653
      OpenUrlPubMed
    73. ↵
      1. Handjani F,
      2. Behazin E,
      3. Sadati MS
      . Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. J Dermatolog Treat. 2014;25(3):249–250pmid:23924070
      OpenUrlPubMed
    74. ↵
      1. Short KA,
      2. Fuller LC,
      3. Higgins EM
      . Double-blind, randomized, placebo-controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatr Dermatol. 2006;23(3):279–281pmid:16780480
      OpenUrlCrossRefPubMed
    75. ↵
      1. Coloe Dosal J,
      2. Stewart PW,
      3. Lin JA,
      4. Williams CS,
      5. Morrell DS
      . Cantharidin for the treatment of molluscum contagiosum: a prospective, double-blinded, placebo-controlled trial. Pediatr Dermatol. 2014;31(4):440–449pmid:22897595
      OpenUrlPubMed
    76. ↵
      1. Katz KA
      . Dermatologists, imiquimod, and treatment of molluscum contagiosum in children: righting wrongs. JAMA Dermatol. 2015;151(2):125–126pmid:25587702
      OpenUrlPubMed
    77. ↵
      1. Silverberg NB,
      2. Sidbury R,
      3. Mancini AJ
      . Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. J Am Acad Dermatol. 2000;43(3):503–507pmid:10954663
      OpenUrlCrossRefPubMed
    78. ↵
      1. Cathcart S,
      2. Coloe J,
      3. Morrell DS
      . Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection. Clin Pediatr (Phila). 2009;48(2):161–165pmid:18936288
      OpenUrlCrossRefPubMed
    79. ↵
      1. Beller M,
      2. Gessner BD
      . An outbreak of tinea corporis gladiatorum on a high school wrestling team. J Am Acad Dermatol. 1994;31(2 pt 1):197–201pmid:8040400
      OpenUrlCrossRefPubMed
    80. ↵
      1. Adams BB
      . Tinea corporis gladiatorum: a cross-sectional study. J Am Acad Dermatol. 2000;43(6):1039–1041pmid:11100020
      OpenUrlCrossRefPubMed
    81. ↵
      1. el Fari M,
      2. Gräser Y,
      3. Presber W,
      4. Tietz HJ
      . An epidemic of tinea corporis caused by Trichophyton tonsurans among children (wrestlers) in Germany. Mycoses. 2000;43(5):191–196pmid:10948818
      OpenUrlCrossRefPubMed
    82. ↵
      1. Hedayati MT,
      2. Afshar P,
      3. Shokohi T,
      4. Aghili R
      . A study on tinea gladiatorum in young wrestlers and dermatophyte contamination of wrestling mats from Sari, Iran. Br J Sports Med. 2007;41(5):332–334pmid:17138633
      OpenUrlAbstract/FREE Full Text
    83. ↵
      1. Ilkit M,
      2. Ali Saracli M,
      3. Kurdak H, et al
      . Clonal outbreak of Trichophyton tonsurans tinea capitis gladiatorum among wrestlers in Adana, Turkey. Med Mycol. 2010;48(3):480–485pmid:19824879
      OpenUrlCrossRefPubMed
    84. ↵
      1. Kohl TD,
      2. Giesen DP,
      3. Moyer J Jr,
      4. Lisney M
      . Tinea gladiatorum: Pennsylvania’s experience. Clin J Sport Med. 2002;12(3):165–171pmid:12011724
      OpenUrlCrossRefPubMed
    85. ↵
      1. Stiller MJ,
      2. Klein WP,
      3. Dorman RI,
      4. Rosenthal S
      . Tinea corporis gladiatorum: an epidemic of Trichophyton tonsurans in student wrestlers. J Am Acad Dermatol. 1992;27(4):632–633pmid:1401322
      OpenUrlCrossRefPubMed
    86. ↵
      1. Yonezawa M,
      2. Idei T,
      3. Takahashi K,
      4. Miyachi Y,
      5. Tanaka S,
      6. Mochizuki T
      . Outbreak of tinea corporis caused by infection with Trichophyton tonsurans in boys belonging to a judo club of a high school in Kyoto. Skin Res. 2004;3(2):220–226
      OpenUrl
    87. ↵
      1. Adams BB
      . Tinea corporis gladiatorum. J Am Acad Dermatol. 2002;47(2):286–290pmid:12140477
      OpenUrlCrossRefPubMed
    88. ↵
      1. Aghamirian MR,
      2. Ghiasian SA
      . A clinico-epidemiological study on tinea gladiatorum in Iranian wrestlers and mat contamination by dermatophytes. Mycoses. 2011;54(3):248–253pmid:19917034
      OpenUrlPubMed
    89. ↵
      1. Ergin S,
      2. Ergin C,
      3. Erdoğan BS,
      4. Kaleli I,
      5. Evliyaoğlu D
      . An experience from an outbreak of tinea capitis gladiatorum due to Trichophyton tonsurans. Clin Exp Dermatol. 2006;31(2):212–214pmid:16487093
      OpenUrlCrossRefPubMed
    90. ↵
      1. Cáceres-Ríos H,
      2. Rueda M,
      3. Ballona R,
      4. Bustamante B
      . Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. J Am Acad Dermatol. 2000;42(1 pt 1):80–84pmid:10607324
      OpenUrlCrossRefPubMed
    91. ↵
      1. Bonifaz A,
      2. Saúl A
      . Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis. Eur J Dermatol. 2000;10(2):107–109pmid:10694308
      OpenUrlPubMed
    92. ↵
      1. Bourlond A,
      2. Lachapelle JM,
      3. Aussems J, et al
      . Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol. 1989;28(6):410–412pmid:2548967
      OpenUrlCrossRefPubMed
    93. ↵
      1. Decroix J,
      2. Fritsch P,
      3. Picoto A,
      4. Thurlimann W,
      5. Degreef H
      . Short-term itraconazole versus terbinafine in the treatment of superficial dermatomycosis of the glabrous skin (tinea corporis or cruris). Eur J Dermatol. 1997;7(5):353–357
      OpenUrl
    94. ↵
      1. Gupta AK,
      2. Adam P,
      3. Dlova N, et al
      . Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr Dermatol. 2001;18(5):433–438pmid:11737692
      OpenUrlCrossRefPubMed
    95. ↵
      1. Friedlander SF,
      2. Aly R,
      3. Krafchik B, et al; Tinea Capitis Study Group
      . Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics. 2002;109(4):602–607pmid:11927703
      OpenUrlAbstract/FREE Full Text
    96. ↵
      1. Fuller LC,
      2. Smith CH,
      3. Cerio R, et al
      . A randomized comparison of 4 weeks of terbinafine vs. 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol. 2001;144(2):321–327pmid:11251566
      OpenUrlCrossRefPubMed
    97. ↵
      1. Memisoglu HR,
      2. Erboz S,
      3. Akkaya S, et al
      . Comparative study of the efficacy and tolerability of 4 weeks of terbinafine therapy with 8 weeks of griseofulvin therapy in children with tinea capitis. J Dermatolog Treat. 1999;10(3):189–193
      OpenUrl
    98. ↵
      1. Gonzalez U,
      2. Seaton T,
      3. Bergus G,
      4. Jacobson J,
      5. Martinez-Monzon C
      . Systemic antifungal therapy for tinea capitis in children.Cochrane Database Syst Rev. 2007;(4):CD004685
    99. ↵
      1. Chen X,
      2. Jiang X,
      3. Yang M, et al
      . Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2016;(5):CD004685pmid:27169520
      OpenUrlPubMed
    100. ↵
      1. Dastghaib L,
      2. Azizzadeh M,
      3. Jafari P
      . Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole. J Dermatolog Treat. 2005;16(1):43–46pmid:15897167
      OpenUrlCrossRefPubMed
    101. ↵
      1. Filho ST,
      2. Cucé LC,
      3. Foss NT,
      4. Marques SA,
      5. Santamaria JR
      . Efficacy, safety and tolerability of terbinafine for Tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1,2 and 4 weeks. J Eur Acad Dermatol Venereol. 1998;11(2):141–146pmid:9784040
      OpenUrlPubMed
    102. ↵
      1. Foster KW,
      2. Friedlander SF,
      3. Panzer H,
      4. Ghannoum MA,
      5. Elewski BE
      . A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. J Am Acad Dermatol. 2005;53(5):798–809pmid:16243128
      OpenUrlCrossRefPubMed
    103. ↵
      1. Hamm H,
      2. Schwinn A,
      3. Bräutigam M,
      4. Weidinger G; The Study Group
      . Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. Br J Dermatol. 1999;140(3):480–482pmid:10233270
      OpenUrlPubMed
    104. ↵
      1. Tey HL,
      2. Tan ASL,
      3. Chan YC
      . Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J Am Acad Dermatol. 2011;64(4):663–670pmid:21334096
      OpenUrlCrossRefPubMed
    105. ↵
      1. Auger P,
      2. Marquis G,
      3. Joly J,
      4. Attye A
      . Epidemiology of tinea pedis in marathon runners: prevalence of occult athlete’s foot. Mycoses. 1993;36(1–2):35–41pmid:8316260
      OpenUrlPubMed
    106. ↵
      1. Kamihama T,
      2. Kimura T,
      3. Hosokawa JI,
      4. Ueji M,
      5. Takase T,
      6. Tagami K
      . Tinea pedis outbreak in swimming pools in Japan. Public Health. 1997;111(4):249–253pmid:9242039
      OpenUrlPubMed
    107. ↵
      1. Patel GA,
      2. Wiederkehr M,
      3. Schwartz RA
      . Tinea cruris in children. Cutis. 2009;84(3):133–137pmid:19842572
      OpenUrlPubMed
    108. ↵
      Evaluation of ciclopirox olamine cream for the treatment of tinea pedis: multicenter, double-blind comparative studies. Clin Ther. 1985;7(4):409–417pmid:3893700
      OpenUrlPubMed
    109. ↵
      1. Aly R,
      2. Fisher G,
      3. Katz I, et al
      . Ciclopirox gel in the treatment of patients with interdigital tinea pedis. Int J Dermatol. 2003;42(suppl 1):29–35pmid:14567368
      OpenUrlPubMed
    110. ↵
      Naftifine gel in the treatment of tinea pedis: two double-blind, multicenter studies. Naftifine Gel Study Group. Cutis. 1991;48(1):85–88pmid:1868748
      OpenUrlPubMed
    111. ↵
      1. Akers WA,
      2. Lane A,
      3. Lynfield Y, et al
      . Sulconazole nitrate 1% cream in the treatment of chronic moccasin-type tinea pedis caused by Trichophyton rubrum. J Am Acad Dermatol. 1989;21(4 pt 1):686–689pmid:2681281
      OpenUrlCrossRefPubMed
    112. ↵
      1. Albanese G,
      2. Di Cintio R,
      3. Giorgetti P,
      4. Galbiati G,
      5. Ciampini M
      . Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder. Mycoses. 1992;35(5–6):157–159pmid:1474987
      OpenUrlPubMed
    113. ↵
      1. Evans EG
      . A comparison of terbinafine (Lamisil) 1% cream given for one week with clotrimazole (Canesten) 1% cream given for four weeks, in the treatment of tinea pedis. Br J Dermatol. 1994;130(suppl 43):12–14pmid:8186134
      OpenUrlPubMed
    114. ↵
      1. Jarratt M,
      2. Jones T,
      3. Kempers S, et al
      . Luliconazole for the treatment of interdigital tinea pedis: a double-blind, vehicle-controlled study. Cutis. 2013;91(4):203–210pmid:23763082
      OpenUrlPubMed
    115. ↵
      1. Barnetson RS,
      2. Marley J,
      3. Bullen M, et al
      . Comparison of one week of oral terbinafine (250 mg/day) with four weeks of treatment with clotrimazole 1% cream in interdigital tinea pedis. Br J Dermatol. 1998;139(4):675–678pmid:9892913
      OpenUrlPubMed
    116. ↵
      1. Gentles JC,
      2. Evans EG,
      3. Jones GR
      . Control of tinea pedis in a swimming bath. BMJ. 1974;2(5919):577–580pmid:4833961
      OpenUrlAbstract/FREE Full Text
    117. ↵
      1. del Palacio Hernandez A,
      2. López Gómez S,
      3. González Lastra F,
      4. Moreno Palancar P,
      5. Iglesias Díez L
      . A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol. 1990;15(3):210–216pmid:2194715
      OpenUrlCrossRefPubMed
    118. ↵
      1. Choudhary S,
      2. Bisati S,
      3. Singh A,
      4. Koley S
      . Efficacy and safety of terbinafine hydrochloride 1% cream vs. sertaconazole nitrate 2% cream in tinea corporis and tinea cruris: a comparative therapeutic trial. Indian J Dermatol. 2013;58(6):457–460pmid:24249898
      OpenUrlPubMed
    119. ↵
      1. Ramam M,
      2. Prasad HR,
      3. Manchanda Y, et al
      . Randomised controlled trial of topical butenafine in tinea cruris and tinea corporis. Indian J Dermatol Venereol Leprol. 2003;69(2):154–158pmid:17642865
      OpenUrlPubMed
    120. ↵
      1. Saple DG,
      2. Amar AK,
      3. Ravichandran G,
      4. Korde KM,
      5. Desai A
      . Efficacy and safety of butenafine in superficial dermatophytoses (tinea pedis, tinea cruris, tinea corporis). J Indian Med Assoc. 2001;99(5):274–275pmid:11676116
      OpenUrlPubMed
    121. ↵
      1. Singal A,
      2. Pandhi D,
      3. Agrawal S,
      4. Das S
      . Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: a randomized, double-blind trial. J Dermatolog Treat. 2005;16(5–6):331–335pmid:16428155
      OpenUrlPubMed
    122. ↵
      1. van Zuuren EJ,
      2. Fedorowicz Z,
      3. El-Gohary M
      . Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. Br J Dermatol. 2015;172(3):616–641
      OpenUrlCrossRefPubMed
    123. ↵
      1. Boonk W,
      2. de Geer D,
      3. de Kreek E,
      4. Remme J,
      5. van Huystee B
      . Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules. Mycoses. 1998;41(11–12):509–514pmid:9919895
      OpenUrlPubMed
    124. ↵
      1. Pariser DM,
      2. Pariser RJ,
      3. Ruoff G,
      4. Ray TL
      . Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris. J Am Acad Dermatol. 1994;31(2 pt 1):232–234
      OpenUrlPubMed
    125. ↵
      1. Kalis B,
      2. Grosshans E,
      3. Binet O, et al
      . Oxiconazole cream versus ketoconazole cream. A prospective, randomized, double-blind, multicenter study in the treatment of inguinocrural dermatophytoses [in French]. Ann Dermatol Venereol. 1996;123(8):447–452pmid:9033712
      OpenUrlPubMed
    126. ↵
      1. Choudhary SV,
      2. Aghi T,
      3. Bisati S
      . Efficacy and safety of terbinafine hydrochloride 1% cream vs eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris. Indian Dermatol Online J. 2014;5(2):128–131pmid:24860743
      OpenUrlPubMed
    127. ↵
      1. Becerro de Bengoa Vallejo R,
      2. Losa Iglesias ME,
      3. Gómez-Martín B,
      4. Sánchez Gómez R,
      5. Sáez Crespo A
      . Application of cantharidin and podophyllotoxin for the treatment of plantar warts. J Am Podiatr Med Assoc. 2008;98(6):445–450pmid:19017852
      OpenUrlPubMed
    128. ↵
      1. López López D,
      2. Vilar Fernández JM,
      3. Losa Iglesias ME, et al
      . Safety and effectiveness of cantharidin-podophylotoxin-salicylic acid in the treatment of recalcitrant plantar warts. Dermatol Ther (Heidelb). 2016;29(4):269–273pmid:27072919
      OpenUrlPubMed
    129. ↵
      1. Koch E,
      2. Clark JM,
      3. Cohen B, et al
      . Management of head louse infestations in the United States-a literature review. Pediatr Dermatol. 2016;33(5):466–472pmid:27595869
      OpenUrlPubMed
    130. ↵
      1. Leulmi H,
      2. Diatta G,
      3. Sokhna C,
      4. Rolain JM,
      5. Raoult D
      . Assessment of oral ivermectin versus shampoo in the treatment of pediculosis (head lice infestation) in rural areas of Sine-Saloum, Senegal. Int J Antimicrob Agents. 2016;48(6):627–632pmid:27866866
      OpenUrlPubMed
    131. ↵
      1. Buescher ES
      . Infections associated with pediatric sport participation. Pediatr Clin North Am. 2002;49(4):743–751pmid:12296530
      OpenUrlPubMed
    132. ↵
      1. Centers for Disease Control and Prevention
      . From the Centers for Disease Control and Prevention. Interstate measles transmission from a ski resort–Colorado, 1994. JAMA. 1994;272(14):1097–1098pmid:7933309
      OpenUrlCrossRefPubMed
    133. ↵
      1. Centers for Disease Control (CDC)
      . Measles at an international gymnastics competition–Indiana, 1991. MMWR Morb Mortal Wkly Rep. 1992;41(7):109–111pmid:1736086
      OpenUrlPubMed
    134. ↵
      1. Centers for Disease Control and Prevention (CDC)
      . Interstate measles transmission from a ski resort–Colorado, 1994. MMWR Morb Mortal Wkly Rep. 1994;43(34):627–629pmid:8065295
      OpenUrlPubMed
    135. ↵
      1. Centers for Disease Control and Prevention (CDC)
      . Multistate measles outbreak associated with an international youth sporting event–Pennsylvania, Michigan, and Texas, August-September 2007. MMWR Morb Mortal Wkly Rep. 2008;57(7):169–173pmid:18288074
      OpenUrlPubMed
    136. ↵
      1. Ehresmann KR,
      2. Hedberg CW,
      3. Grimm MB,
      4. Norton CA,
      5. MacDonald KL,
      6. Osterholm MT
      . An outbreak of measles at an international sporting event with airborne transmission in a domed stadium. J Infect Dis. 1995;171(3):679–683pmid:7876616
      OpenUrlCrossRefPubMed
    137. ↵
      1. Sasaki A,
      2. Suzuki H,
      3. Sakai T,
      4. Sato M,
      5. Shobugawa Y,
      6. Saito R
      . Measles outbreaks in high schools closely associated with sporting events in Niigata, Japan. J Infect. 2007;55(2):179–183pmid:17560656
      OpenUrlPubMed
    • Copyright © 2017 by the American Academy of Pediatrics
    PreviousNext
    Back to top

    Advertising Disclaimer »

    In this issue

    Pediatrics
    Vol. 140, Issue 4
    1 Oct 2017
    • Table of Contents
    • Index by author
    View this article with LENS
    PreviousNext
    Email Article

    Thank you for your interest in spreading the word on American Academy of Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Infectious Diseases Associated With Organized Sports and Outbreak Control
    (Your Name) has sent you a message from American Academy of Pediatrics
    (Your Name) thought you would like to see the American Academy of Pediatrics web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Request Permissions
    Article Alerts
    Log in
    You will be redirected to aap.org to login or to create your account.
    Or Sign In to Email Alerts with your Email Address
    Citation Tools
    Infectious Diseases Associated With Organized Sports and Outbreak Control
    H. Dele Davies, Mary Anne Jackson, Stephen G. Rice, COMMITTEE ON INFECTIOUS DISEASES, COUNCIL ON SPORTS MEDICINE AND FITNESS
    Pediatrics Oct 2017, 140 (4) e20172477; DOI: 10.1542/peds.2017-2477

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Infectious Diseases Associated With Organized Sports and Outbreak Control
    H. Dele Davies, Mary Anne Jackson, Stephen G. Rice, COMMITTEE ON INFECTIOUS DISEASES, COUNCIL ON SPORTS MEDICINE AND FITNESS
    Pediatrics Oct 2017, 140 (4) e20172477; DOI: 10.1542/peds.2017-2477
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Print
    Download PDF
    Insight Alerts
    • Table of Contents

    Jump to section

    • Article
      • Abstract
      • Introduction
      • Organisms Associated With Infections in Athletes
      • Infections Primarily Spread by Contact Transmission
      • Infections Primarily Spread by Airborne or Droplet Route
      • Lead Authors
      • Committee on Infectious Diseases, 2016–2017
      • Ex Officio
      • Liaisons
      • Staff
      • Council on Sports Medicine and Fitness Executive Committee, 2016–2017
      • Liaisons
      • Consultant
      • Staff
      • Footnotes
      • References
    • Figures & Data
    • Supplemental
    • Info & Metrics
    • Comments

    Related Articles

    • PubMed
    • Google Scholar

    Cited By...

    • No citing articles found.
    • Google Scholar

    More in this TOC Section

    • Ethical Considerations in Pediatricians’ Use of Social Media
    • 2021 Recommendations for Preventive Pediatric Health Care
    • Recommended Childhood and Adolescent Immunization Schedule: United States, 2021
    Show more From the American Academy of Pediatrics

    Similar Articles

    Subjects

    • Current Policy
    • Infectious Disease
      • Infectious Disease
    • AAP Policy Collections by Authoring Entities
      • Council on Sports Medicine and Fitness
      • Committee on Infectious Diseases
    • Journal Info
    • Editorial Board
    • Editorial Policies
    • Overview
    • Licensing Information
    • Authors/Reviewers
    • Author Guidelines
    • Submit My Manuscript
    • Open Access
    • Reviewer Guidelines
    • Librarians
    • Institutional Subscriptions
    • Usage Stats
    • Support
    • Contact Us
    • Subscribe
    • Resources
    • Media Kit
    • About
    • International Access
    • Terms of Use
    • Privacy Statement
    • FAQ
    • AAP.org
    • shopAAP
    • Follow American Academy of Pediatrics on Instagram
    • Visit American Academy of Pediatrics on Facebook
    • Follow American Academy of Pediatrics on Twitter
    • Follow American Academy of Pediatrics on Youtube
    • RSS
    American Academy of Pediatrics

    © 2021 American Academy of Pediatrics